How to Predict Hepatotoxicity and Drug Clearance Ahead of Clinical Trials Using Liver-on-a-Chip
Filed under: ADME, Disease modeling, Drug metabolism, and Safety toxicology
Video content if present
Current in vitro approaches for investigational toxicology, drug metabolism (DMPK) and safety are limited.
Furthermore, they are not fully representative of human response; therefore, drugs showing acceptable preclinical toxicity often fail in human clinical trials, and accurately predicting human drug exposure for new compounds is challenging and costly.
Watch this webinar to learn:
Developing liver-on-chip MPS systems and comparison to traditional in vitro liver approaches
Modeling human hepatotoxicity prediction using liver-MPS
Modeling human drug clearance using liver-MPS
Data validating and translatability between organ-on-chips and human
Accessing CN Bio MPS technology
Microphysiological Systems (MPS), or Organ-on-chip (OOC) technologies are a trending way to bridge the gap between traditional DMPK/toxicology assays and human trials by providing more robust and reliable data that translate into clinical outcomes.
CN Bio offers preclinical investigational toxicology and DMPK services using its proprietary, industry-proven PhysioMimix® OOC technology and liver-on-a-chip model. In this webinar, we will share our latest advances in investigational toxicology, drug clearance and drug safety, highlighting how the translatable, human-relevant data generated using CN Bio’s liver-on-a-chip model can be used to support (or call into question) the conclusions of internal pre-clinical studies, helping you to make data driven decisions with greater confidence.
